Administration of 4-(α-L-Rhamnosyloxy)-benzyl isothiocyanate delays disease phenotype in SOD1G93A Rats: A transgenic model of amyotrophic lateral sclerosis

Maria Galuppo, Sabrina Giacoppo, Renato Iori, Gina Rosalinda De Nicola, Placido Bramanti, Emanuela Mazzon

Research output: Contribution to journalArticlepeer-review

Abstract

4-(α-L-Rhamnosyloxy)-benzyl glucosinolate (glucomoringin, GMG) is a compound found in Moringa oleifera seeds. Myrosinase-catalyzed hydrolysis at neutral pH of GMG releases the biologically active compound 4-(α-L-rhamnosyloxy)-benzyl isothiocyanate (GMG-ITC). The present study was designed to test the potential therapeutic effectiveness of GMG-ITC to counteract the amyotrophic lateral sclerosis (ALS) using SOD1tg rats, which physiologically develops SOD1G93A at about 16 weeks of life, and can be considered a genetic model of disease. Rats were treated once a day with GMG (10 mg/Kg) bioactivated with myrosinase (20 μL/rat) via intraperitoneal (i.p.) injection for two weeks before disease onset and the treatment was prolonged for further two weeks before the sacrifice. Immune-inflammatory markers as well as apoptotic pathway were investigated to establish whether GMG-ITC could represent a new promising tool in clinical practice to prevent ALS. Achieved data display clear differences in molecular and biological profiles between treated and untreated SOD1tg rats leading to guessing that GMG-ITC can interfere with the pathophysiological mechanisms at the basis of ALS development. Therefore, GMG-ITC produced from myrosinase-catalyzed hydrolysis of pure GMG could be a candidate for further studies aimed to assess its possible use in clinical practice for the prevention or to slow down this disease.

Original languageEnglish
Article number259417
JournalBioMed Research International
Volume2015
DOIs
Publication statusPublished - 2015

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Fingerprint Dive into the research topics of 'Administration of 4-(α-L-Rhamnosyloxy)-benzyl isothiocyanate delays disease phenotype in SOD1<sup>G93A</sup> Rats: A transgenic model of amyotrophic lateral sclerosis'. Together they form a unique fingerprint.

Cite this